APR Apria Inc

As previously announced, on January 7, 2022, Apria, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among the Company, Owens & Minor, Inc., a Virginia corporation (“Parent”), and StoneOak Merger Sub Inc., a Delaware corporation and an indirect, wholly owned subsidiary of Parent (“Merger Sub”), pursuant to which Merger Sub will be merged with and into the Company (the “Merger”) with the Company surviving the Merger as an indirect, wholly owned subsidiary of Parent.

Supplemental Disclosures in Connection with Transaction Litigation

This Current Report on Form 8-K (this “Form 8-K”) is being filed to update and supplement the definitive proxy statement (the “Proxy Statement”) filed by the Company on February 22, 2022 and mailed by the Company to its stockholders commencing on February 22, 2022. The information contained in this Form 8-K is incorporated by reference into the Proxy Statement. Terms used in this Form 8-K, but not otherwise defined, shall have the meanings ascribed to such terms in the Proxy Statement.

Following the announcement of the Merger Agreement and as of the date of this Form 8-K, five lawsuits have been filed in connection with the Merger on behalf of purported individual stockholders of the Company—one lawsuit filed on February 10, 2022 in the United States District Court for the Southern District of New York, one lawsuit filed on February 16, 2022 in the United States District Court for the District of Delaware, one lawsuit filed on February 23, 2022 in the United States District Court for the District of Colorado, one lawsuit filed on March 8, 2022 in the United States District Court for the Eastern District of Pennsylvania and one lawsuit filed on March 11, 2022 in the United States District Court for the Eastern District of New York. These lawsuits, Massie vs Apria, Inc. et al., Case No. 1:22-cv-01175-JPO, Waterman vs Apria, Inc. et al., Case No. 1:22-cv-00211-MN, Bushansky vs Apria, Inc. et al., Case No. 1:22-cv-00462, Whitfield vs Apria, Inc. et al., Case No. 2:22-cv-00873, and Lapekes vs Apria, Inc. et al., Case No. 1:22-cv-01366 (collectively, the “Actions”), name the Company and individual officers and members of the Company’s board of directors as defendants. The Actions allege, among other things, that the defendants failed to disclose certain information relating to the Company’s financial projections set forth in the Proxy Statement.

The Company believes that the Actions are without merit and that no further disclosure is required to supplement the Proxy Statement under applicable law; however, to eliminate the burden, expense, and uncertainties inherent in such litigation, and without admitting any liability or wrongdoing, the Company has agreed to make certain supplemental disclosures to the Proxy Statement as set forth below. Nothing in these supplemental disclosures shall be deemed an admission of the legal necessity or materiality under applicable law of any of the disclosures set forth herein. The defendants have vigorously denied, and continue vigorously to deny, that they have committed any violation of law or engaged in any of the wrongful acts that were alleged in the Actions. In consideration for such supplemental disclosures by the Company, plaintiffs in the Actions have agreed to voluntarily dismiss the Actions.

Supplements to the Proxy Statement

The supplemental disclosures to the Proxy Statement set forth in this Form 8-K below should be read alongside the Proxy Statement, which should be read in its entirety, and to the extent that information in this Form 8-K differs from or updates information contained in the Proxy Statement, this Form 8-K shall supersede the information in the Proxy Statement. Defined terms used but not otherwise defined herein have the meanings set forth in the Proxy Statement.

1.    The section of the Proxy Statement entitled “The Merger—Opinion of Apria’s Financial Advisor” is hereby amended and supplemented as follows:

A.    By adding the underlined and bolded text, and removing the strikethrough text, below from the first paragraph under the heading entitled “Illustrative Present Value of Future Share Price Analysis”:

Goldman Sachs performed an analysis of the implied present value of an illustrative future value per share of Apria common stock, which is designed to provide an indication of the present value of a theoretical future value of a company’s equity as a function of such company’s financial multiples. Using the Forecasts, Goldman Sachs first calculated illustrative implied future enterprise values of Apria as of September 30 for each of fiscal years 2021, 2022 and 2023 by applying (x) enterprise value to next-twelve-month (“NTM”) Adjusted EBITDA Less Patient Equipment Capex multiples ranging from 9.5x to 11.5x to (y) the estimated NTM Adjusted EBITDA Less Patient Equipment Capex for the NTM beginning on September 30, 2021, September 30, 2022 and September 30, 2023, respectively. The enterprise value to NTM Adjusted EBITDA Less Patient Equipment Capex multiples used in this analysis were derived by Goldman Sachs utilizing its professional judgment and experience, taking into account, among other things, current and historical NTM Adjusted EBITDA Less Patient Equipment Capex multiples for Apria. Goldman Sachs then subtracted the net debt of Apria of $385 million as of September 30, 2021, as provided by management of Apria, from the respective illustrative implied future enterprise values in order to derive a range of illustrative implied future equity values for Apria as of September 30 for each of fiscal years 2021, 2022 and 2023. Goldman Sachs then divided such illustrative implied future equity values by the number of 38.59 million fully-diluted shares of Apria common stock outstanding (using the treasury stock method) as of January 5, 2022, as provided by management of Apria, to derive a range of implied future share prices as of September 30, 2021, September 30, 2022 and September 30, 2023, respectively. Goldman Sachs then discounted such implied future share prices back to September 30, 2021 using an illustrative discount rate of 8.8%, reflecting an estimate of Apria’s cost of equity. Goldman Sachs derived such discount rate by application of the Capital Asset Pricing Model, which requires certain company-specific inputs, including a beta for Apria, as well as certain financial metrics for the United States financial markets generally. This analysis resulted in a range of implied present values of $29.72 to $37.16 per share of Apria common stock.

B.    By adding the underlined and bolded text, and removing the strikethrough text, below from the third paragraph under the heading entitled “Illustrative Discounted Cash Flow Analysis”:

Goldman Sachs derived ranges of illustrative enterprise values for Apria by adding the ranges of present values it derived above. Goldman Sachs then subtracted from the range of illustrative enterprise values it derived for Apria the net debt of Apria of $385 million as of September 30, 2021, as provided by the management of Apria, to derive a range of illustrative equity values for Apria. Goldman Sachs then divided the range of illustrative equity values it derived by the number of 38.59 million fully-diluted shares of Apria common stock outstanding (using the treasury stock method) as of January 5, 2022, as provided by the management of Apria, to derive a range of illustrative present values per share of Apria common stock. Using the Forecasts, and as set forth in the January 7 Presentation, this analysis indicated a range of illustrative present values per share of Apria common stock ranging from $31.74 to $43.99, and using the Corrected Forecasts, this analysis indicated a range of illustrative present values per share of Apria common stock ranging from $32.16 to $44.43.

C.    By adding the underlined and bolded text and summary table below from the first paragraph under the heading entitled “Premia Paid Analysis”:

Goldman Sachs reviewed and analyzed, using publicly available information, the acquisition premia for transactions announced during the period from January 2017 through December 2021 that involved the acquisition of all of the outstanding equity of a U.S. public company with an enterprise value of $500,000,000 to $2,000,000,000, including: (i) 60 such transactions for the calendar year 2017, (ii) 57 such transactions for the calendar year 2018, (iii) 42 such transactions for the calendar year 2019, (iv) 36 such transactions for the calendar year 2020 and (v) 55 such transactions for the calendar year 2021. For such period, using publicly available information, Goldman Sachs calculated the median, 25th percentile and 75th percentile premiums of the price paid in these 250 transactions relative to the target’s last

undisturbed closing stock price prior to announcement of the transaction. This analysis indicated a median premium of 16%, a 25th percentile premium of 7% and a 75th percentile premium of 25% during such period. Using this analysis, Goldman Sachs applied a reference range of illustrative premiums of 7% to 25% to the undisturbed closing price per share of Apria common stock of $30.18 as of January 5, 2022, and calculated a range of implied equity values per share of Apria common stock of $32.29 to $37.73 per share of Apria common stock. The following table shows a summary of the results of this review:

2.    The section of the Proxy Statement entitled “Certain Financial Projections” is hereby amended and supplemented as follows:

Under the caption “Financial Projections”, the table and related footnotes on page 56 of the proxy statement are replaced in their entirety as follows: